These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 25326640)

  • 21. [Systemic therapy of soft tissue sarcomas].
    Semenova AI; Protsenko SA; Komarov YI; Teletaeva GM; Latipova DH; Novik AV
    Vopr Onkol; 2015; 61(2):252-8. PubMed ID: 26087607
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Signaling inhibitors in metastatic renal cell carcinoma.
    Escudier B
    Cancer J; 2008; 14(5):325-9. PubMed ID: 18836338
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Angiogenesis inhibitors for the systemic treatment of metastatic renal cell carcinoma: sunitinib, sorafenib, bevacizumab and temsirolimus].
    de Mulder PH; Haanen JB; Sleijfer S; Kruit WH; Gietema JA; Richel DJ; Groenewegen G; Voest EE; van den Eertwegh AJ; Osanto S; Jansen RL; Mulders PF
    Ned Tijdschr Geneeskd; 2008 Feb; 152(7):371-5. PubMed ID: 18380383
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New therapeutic strategies for renal cell carcinoma.
    Wood LS
    Urol Nurs; 2010; 30(1):40-53. PubMed ID: 20359144
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-proliferative but not anti-angiogenic tyrosine kinase inhibitors enrich for cancer stem cells in soft tissue sarcoma.
    Canter RJ; Ames E; Mac S; Grossenbacher SK; Chen M; Li CS; Borys D; Smith RC; Tellez J; Sayers TJ; Monjazeb AM; Murphy WJ
    BMC Cancer; 2014 Oct; 14():756. PubMed ID: 25301268
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Angiogenesis inhibition: review of the activity of sorafenib, sunitinib and bevacizumab].
    Barrascout E; Medioni J; Scotte F; Ayllon J; Mejean A; Cuenod CA; Tartour E; Elaidi R; Oudard S
    Bull Cancer; 2010; 97():29-43. PubMed ID: 20418202
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma.
    Margulis V; Matin SF; Tannir N; Tamboli P; Swanson DA; Jonasch E; Wood CG
    J Urol; 2008 Jul; 180(1):94-8. PubMed ID: 18485389
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An update on targeted therapy in metastatic renal cell carcinoma.
    Lombardi G; Zustovich F; Donach M; Dalla Palma M; Nicoletto O; Pastorelli D
    Urol Oncol; 2012; 30(3):240-6. PubMed ID: 20456985
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeted therapies in metastatic renal cancer in 2009.
    Bastien L; Culine S; Paule B; Ledbai S; Patard JJ; de la Taille A
    BJU Int; 2009 May; 103(10):1334-42. PubMed ID: 19338565
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma.
    Fernández-Pello S; Hofmann F; Tahbaz R; Marconi L; Lam TB; Albiges L; Bensalah K; Canfield SE; Dabestani S; Giles RH; Hora M; Kuczyk MA; Merseburger AS; Powles T; Staehler M; Volpe A; Ljungberg B; Bex A
    Eur Urol; 2017 Mar; 71(3):426-436. PubMed ID: 27939075
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New treatment approaches in metastatic renal cell carcinoma.
    Mancuso A; Sternberg CN
    Curr Opin Urol; 2006 Sep; 16(5):337-41. PubMed ID: 16905978
    [TBL] [Abstract][Full Text] [Related]  

  • 32. VEGF-targeted therapy in renal cell carcinoma: active drugs and active choices.
    Rini BI
    Curr Oncol Rep; 2006 Mar; 8(2):85-9. PubMed ID: 16507216
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic Targets for Bone and Soft-Tissue Sarcomas.
    Miwa S; Yamamoto N; Hayashi K; Takeuchi A; Igarashi K; Tsuchiya H
    Int J Mol Sci; 2019 Jan; 20(1):. PubMed ID: 30621224
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of the incorporation of tyrosine kinase inhibitor agents on the treatment of patients with a diagnosis of advanced renal cell carcinoma: study based on experience at the Hospital Universitario Central de Asturias.
    Muriel C; Esteban E; Corral N; Fonseca PJ; Luque M; Berros JP; Fernández Y; Blay P; Fra J; Villanueva N; Sanmamed M; Pardo P; Izquierdo M; Vieitez JM; Estrada E; Lacave ÁJ
    Clin Transl Oncol; 2010 Aug; 12(8):562-7. PubMed ID: 20709657
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [New possibilities of targeted therapy in the treatment of hepatocellular carcinoma with the help of molecular biology].
    Hagymási K; Tulassay Z
    Orv Hetil; 2010 Oct; 151(43):1763-8. PubMed ID: 20940115
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.
    Hutson TE; Escudier B; Esteban E; Bjarnason GA; Lim HY; Pittman KB; Senico P; Niethammer A; Lu DR; Hariharan S; Motzer RJ
    J Clin Oncol; 2014 Mar; 32(8):760-7. PubMed ID: 24297950
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel drugs for renal cell carcinoma.
    Vakkalanka BK; Bukowski RM
    Expert Opin Investig Drugs; 2008 Oct; 17(10):1501-16. PubMed ID: 18808310
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of targeted therapy for metastatic renal cell carcinoma in the elderly patient population.
    Khambati HK; Choueiri TK; Kollmannsberger CK; North S; Bjarnason GA; Vaishampayan UN; Wood L; Knox JJ; Tan MH; MacKenzie MJ; Donskov F; Rini BI; Heng DY;
    Clin Genitourin Cancer; 2014 Oct; 12(5):354-8. PubMed ID: 24819320
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].
    Miller K; Bergmann L; Jäger E; Jakse G; Wirth M; Keilholz U;
    Aktuelle Urol; 2009 Jan; 40(1):27-30. PubMed ID: 19177318
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Molecular biology of sarcoma and therapeutic choices].
    Dufresne A; Cassier P; Heudel P; Pissaloux D; Wang Q; Blay JY; Ray-Coquard I
    Bull Cancer; 2015 Jan; 102(1):6-16. PubMed ID: 25609490
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.